The historical rank and industry rank for Shin Nippon Biomedical Laboratories's Return-on-Tangible-Asset or its related term are showing as below:
SBLOF'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -6.29 Med: 5.74 Max: 18.79
Current: 4.75
During the past 13 years, Shin Nippon Biomedical Laboratories's highest Return-on-Tangible-Asset was 18.79%. The lowest was -6.29%. And the median was 5.74%.
SBLOF's Return-on-Tangible-Asset is ranked better than 69.3% of 215
companies
in the Medical Diagnostics & Research industry
Industry Median: -2.4
vs SBLOF: 4.75
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Shin Nippon Biomedical Laboratories Return-on-Tangible-Asset Related Terms
Shin Nippon Biomedical Laboratories Return-on-Tangible-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SBLOF vs TMO, DHR, IDXX: Return-on-Tangible-Asset Comparison
For the Diagnostics & Research subindustry, Shin Nippon Biomedical Laboratories's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shin Nippon Biomedical Laboratories Return-on-Tangible-Asset vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Shin Nippon Biomedical Laboratories's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Shin Nippon Biomedical Laboratories's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 8.51% mean?
Shin Nippon Biomedical Laboratories (SBLOF) has a Return-on-Tangible-Asset of 8.51% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Shin Nippon Biomedical Laboratories and its competitors. This is 48% above median its historical median of 5.74. According to the industry distribution chart, Shin Nippon Biomedical Laboratories ranks #66 out of 215 companies in the Medical Diagnostics & Research industry, placing it in the top 30.7%.
Is Shin Nippon Biomedical Laboratories' Return-on-Tangible-Asset too high?
Shin Nippon Biomedical Laboratories' current Return-on-Tangible-Asset of 8.51% is 48% above median its 10-year median of 5.74. Based on the distribution chart, Shin Nippon Biomedical Laboratories ranks #66 out of 215 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Shin Nippon Biomedical Laboratories has a GF Score™ of 74/100, reflecting its overall financial health beyond just this single metric.
How does Shin Nippon Biomedical Laboratories' Return-on-Tangible-Asset compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Shin Nippon Biomedical Laboratories ranks #66 out of 215 companies for Return-on-Tangible-Asset. This puts Shin Nippon Biomedical Laboratories in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Diagnostics & Research company?
A good Return-on-Tangible-Asset depends on the Medical Diagnostics & Research industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Shin Nippon Biomedical Laboratories and its competitors. Shin Nippon Biomedical Laboratories's current Return-on-Tangible-Asset is 8.51%, which is 48% above median its own 10-year median of 5.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shin Nippon Biomedical Laboratories stock overvalued right now?
Shin Nippon Biomedical Laboratories (SBLOF) has a current Return-on-Tangible-Asset of 8.51%. The stock's GF Value™ is $13.86, compared to a current price of $9.16 — trading 33.9% below its estimated fair value. The current Return-on-Tangible-Asset is 8.51%, which is 48% above median its 10-year median of 5.74. Shin Nippon Biomedical Laboratories' overall GF Score™ is 74/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Shin Nippon Biomedical Laboratories (SBLOF), the current Return-on-Tangible-Asset is 8.51% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shin Nippon Biomedical Laboratories (SBLOF) Overvalued in 2026?
Based on GuruFocus' analysis, Shin Nippon Biomedical Laboratories stock appears to be undervalued.
The current stock price of $9.16 is trading 33.9% below its estimated GF Value™ of $13.86.
Key valuation signals for SBLOF:
Return-on-Tangible-Asset: 8.51% (48% above median its 10-year median of 5.74)
GF Value™: $13.86 vs. price of $9.16 (33.9% below fair value)
No single metric tells the full story. See the SBLOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shin Nippon Biomedical Laboratories Business Description
Shin Nippon Biomedical Laboratories Ltd provides pre-clinical testing services in the pharmaceutical industry in Japan. The company provides a range of services such as pre-clinical and analysis studies, contracted clinical trials, SMO, CRO, translational research and cancer treatment.
74GF Score
Get the complete analysis for SBLOF
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SBLOF has been successfully added to your 
